Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Oxford Genetics Licenses Expression Vectors To CA-Based Twist Bioscience

By Mike Botta | November 17, 2017

Oxford Genetics, a provider of synthetic biology-based technologies for biologics discovery, development, and delivery has signed a new licensing agreement with Twist Bioscience Corporation, a company that offers rapid, high-quality synthetic DNA.

Under the arrangement, Oxford Genetics will supply Twist Bioscience with its SnapFast technology platform to provide a broad range of application-specific expression vectors, which Twist will use to clone synthesized DNA for its customer base.

SnapFast is a LEGO-like core DNA system that serves as a foundational platform for four technology areas that are built to improve biologics.

Oxford  specializes in the design of application specific vectors, which is a culmination of access to bioinformatics, the generation of extensive biological data, and continual refinement. The vectors also grant access to the wider SnapFast ecosystem that allows Twist to switch between all of Oxford Genetics’ vectors, allowing for efficient future changes and additions.

“By complementing our ability to provide high throughput synthetic genes with a wide range of customized vectors from Oxford Genetics, we accelerate our customer’s workflow, allowing them to solve more complex problems while saving both time and resources,” Emily M. Leproust, Ph.D., CEO of Twist Bioscience commented. “Importantly, it enables us to reach the large group of customers who order smaller quantities of genes in standard vectors.”

(Source: Oxford Genetics)


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE